Talon Therapeutics Inc. (TLON)’s experimental blood-cancer treatment, based on a compound from the rosy periwinkle flower, is attracting potential partners and buyers, Chief Executive Officer Steven Deitcher said. The U.S. Food and Drug Administration is set to decide by Aug. 12 whether to approve the medicine, a treatment called Marqibo for acute lymphoblastic leukemia, for patients who have failed at least two other therapies, giving the South San Francisco-based company its first marketable product.
